+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin



Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin



Tumori 95(6): 687-690



Association between pegylated liposomal doxorubicin-based regimens and palmar-plantar erythrodysesthesia have just been emphasized, whereas the relationship between previous treatment and palmar-plantar erythrodysesthesia is still a matter of discussion. We evaluate the relationship between previous chemotherapy treatments and the development of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin-based regimens. Between January 2005 and November 2006, 92 patients received regimens including pegylated liposomal doxorubicin. Patients were divided into three groups based on pegylated liposomal doxorubicin dosing interval length, different dose chosen, and previous chemotherapy. Among pretreated patients receiving regimens including 30 mg/m2 of pegylated liposomal doxorubicin repeated every three weeks, the incidence of palmar-plantar erythrodysesthesia was not significantly higher than in unpretreated patients receiving the same weekly schedule (P = 0.4). There was no difference in the incidence of palmar-plantar erythrodysesthesia between pretreated patients with regimens including 30 mg/m2 of pegylated liposomal doxorubicin every three weeks and pretreated patients receiving 20 mg/m2 of pegylated liposomal doxorubicin every two weeks (P = 0.8). The prevalence of palmar-plantar erythrodysesthesia observed in the unpretreated group exposed to 30 mg/m2 every three weeks was comparable to that of the pretreated group receiving 20 mg/m2 biweekly (P = 0.3). However, excluding all the patients who developed grade 1 palmar-plantar erythrodysesthesia, the incidence of grade 2 and 3 palmar-plantar erythrodysesthesia observed in pretreated patients receiving regimens including 20 mg/m2 of pegylated liposomal doxorubicin biweekly was significantly higher than in unpretreated patients receiving 30 mg/m2 of pegylated liposomal doxorubicin every three weeks (P = 0.001). Our findings indicate that the pretreatment is not involved in the increased incidence of any grade palmar-plantar erythrodysesthesia. On the contrary, the study could suggest that the type of previous treatment may be an important factor in the development of more severe forms of palmar-plantar erythrodysesthesia.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053791768

Download citation: RISBibTeXText

PMID: 20210230


Related references

The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia. European Journal of Gynaecological Oncology 30(4): 387-388, 2009

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin. Gynecologic Oncology 103(1): 72-74, 2006

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70(2): 141-146, 2006

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia. Gynecology and Minimally Invasive Therapy 7(1): 44-45, 2018

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 23(3): 244-249, 2015

Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecologic Oncology 131(3): 683-688, 2014

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Annals of Oncology 18(7): 1159-1164, 2007

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer ChemoTherapy and Pharmacology 44(4): 303-306, 1999

Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience. Oncology 73(3-4): 277-278, 2008

Overall quality of life (QoL) is not meaningfully affected by severity of pegylated liposomal doxorubicin (PLD)-associated palmar-plantar erythrodysesthesia (PPE) among women with metastatic breast cancer. Journal of Clinical Oncology 23(16_Suppl): 788-788, 2016

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer ChemoTherapy and Pharmacology 76(5): 1033-1039, 2016

Amifostine in the prevention of liposomal doxorubicin induced palmar-plantar erythrodysesthesia. Blood 98(11 Part 2): 309b, November 16, 2001

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecologic Oncology 114(2): 219-224, 2009

Palmar-plantar erythrodysaesthesia during pegylated liposomal doxorubicin treatment. Współczesna Onkologia 3: 164-167, 2011

Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study. Farmacia Hospitalaria 35(1): 46-47, 2011